

Drug Coverage Decision for B.C. PharmaCare

About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

Details of Drug Reviewed

Drug	glycopyrronium
Brand Name	Seebri [®]
Dosage Form(s)	50 µg capsule for inhalation
Manufacturer	Novartis Pharmaceuticals Canada Inc.
Submission Review	New Submission
Use Reviewed	Glycopyrronium (Seebri [®]) is reviewed for the treatment of chronic obstructive pulmonary disease (COPD)
Common Drug Review (CDR)	CDR recommended glycopyrronium be listed with criteria: http://www.cadth.ca/media/cdr/complete/cdr_complete_Seebri-May-17-13.pdf
Drug Benefit Council (DBC)	DBC met on July 15, 2013. DBC considered the following: the final review completed by the Common Drug Review (CDR), which included clinical and pharmacoeconomic evidence review material and the recommendation from the Canadian Drug Expert Committee (CDEC); Clinical Practice Review from one Specialist, Manufacturer comments; responses to Patient Input Questionnaires from one patient and one patient group; and a Budget Impact Analysis.
Drug Coverage Decision	Limited Coverage benefit with criteria http://www.health.gov.bc.ca/pharmacare/sa/criteria/restricted/glycopyrronium.html
Date	September 19, 2013
Reason(s)	Drug coverage decision is consistent with the DBC recommendation. <ul style="list-style-type: none"> • Glycopyrronium was similar to tiotropium with respect to efficacy and safety. • Based on economic considerations and the submitted product price, the drug was cost effective.
Other Information	None

The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council](#) gives advice to the Ministry. The Council looks at:

- advice from a national group called the Common Drug Review
- whether the drug is safe and effective
- whether it is a good value for the people of B.C. and the drugs cost
- the ethics of covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes a decision based on many factors, including:

- advice from the Council
- drugs used to treat similar medical conditions that B.C. PharmaCare already covers
- the overall cost of covering the drug

For more information about the B.C. Drug Review Process, please visit
<http://www.health.gov.bc.ca/pharmacare/outgoing/drugrevproc2.pdf>.

To find out more about the Pharmaceutical Services Division and the PharmaCare program, visit
www.health.gov.bc.ca/pharmacare.

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.